FIRDAPSE IS THE RECOMMENDED FIRST-LINE TREATMENT FOR LAMBERT-EATON MYASTHENIC SYNDROME (LEMS)1

The only FDA-approved LEMS treatment for adults and pediatric patients 6 years of age and older1,2

A UNIQUE COMPOUND

FIRDAPSE was the first FDA-approved therapy containing amifampridine, a voltage-gated potassium channel blocker that targets the presynaptic nerve terminal of neuromuscular junctions.28-30*

Chemical structure of FIRDAPSE compound
Amifampridine phosphate
(3,4-diaminopyridine phosphate)

EXTENSIVELY TESTED

FIRDAPSE has been tested in more than 70 clinical and nonclinical studies, including two positive Phase 3 studies, over a 9‑year period.2,31

In clinical trials, FIRDAPSE demonstrated clinically meaningful preservation in muscle strength and patient satisfaction2-4:

Chemical structure of FIRDAPSE compound
Amifampridine phosphate
(3,4-diaminopyridine phosphate)

CHANGING LIVES

~3,000 people in the US are living with the challenges of LEMS

people in the US are living with the challenges of LEMS11

>1000 people have put their lives back in motion with FIRDAPSE

people have put their lives back in motion with FIRDAPSE31

*The mechanism by which FIRDAPSE exerts its therapeutic effect in patients with LEMS has not been fully elucidated.
FIRDAPSE is a broad-spectrum potassium channel blocker.2

FIRDAPSE MECHANISM OF ACTION (MOA)

Illustrated rendering of FIRDAPSE MOA

See the mechanism in action

Watch this MOA animation to better understand how FIRDAPSE helps restore communication between neurons and muscle receptors.